InviMeds Health’s Post

𝗥𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗔𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀 𝗗𝗿𝘂𝗴𝘀: 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗠𝗮𝗻𝗮𝗴𝗶𝗻𝗴 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗜𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 Rheumatoid arthritis (RA) is a debilitating autoimmune disease affecting millions worldwide. Treatment for RA has evolved to address both the symptoms and the underlying causes of inflammation and joint damage. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and corticosteroids are widely used to alleviate pain and inflammation in the short term, while Disease Modifying Anti-rheumatic Drugs (DMARDs) and biologic response modifiers target the root of the disease, aiming to prevent joint damage and slow disease progression. 𝐒𝐚𝐦𝐩𝐥𝐞 𝐓𝐎𝐂: https://lnkd.in/gYwgy-_b The rheumatoid arthritis (RA) drugs market is a dynamic sector driven by rising prevalence, advancements in treatment options, and increasing awareness of the condition. As of 2023, the global market is valued in the billions, with a projected growth rate fueled by an aging population and higher healthcare expenditure. Biologic therapies, including TNF inhibitors (like adalimumab and etanercept) and newer agents targeting IL-6 and JAK pathways, dominate the market due to their efficacy in managing moderate to severe RA. DMARDs, particularly methotrexate, remain foundational in treatment strategies, while NSAIDs and corticosteroids continue to provide symptomatic relief. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/gFPfhT3B Emerging therapies, including biosimilars, are expected to enhance accessibility and affordability, reshaping competitive dynamics. Key players include major pharmaceutical companies like AbbVie, Amgen, and Johnson & Johnson, who invest heavily in research and development to innovate and expand their portfolios. The global Rheumatoid Arthritis Drugs Market is growing rapidly as new biologic therapies and advanced treatments are developed. These medications offer hope for better disease management, significantly improving the quality of life for those living with RA by reducing pain, improving mobility, and minimizing long-term joint damage. Cano Health Kroger Specialty Pharmacy Pivot Physical Therapy, an Athletico Company Soleo Health Illinois Bone & Joint Institute IVX Health KKT Ipca Laboratories Limited Garvan Institute of Medical Research #RheumatoidArthritis #AutoimmuneDisease #RATreatment #NSAIDs #DMARDs #Biologics #ChronicIllness #Pharmaceuticals #MarketTrends #HealthcareInnovation #PatientCare

Evaluating the Cost-Effectiveness of Tofacitinib in Rheumatoid Arthritis Treatment This study examines whether tofacitinib is a cost-effective alternative to other treatments for rheumatoid arthritis. The findings suggest that tofacitinib may not be cost-effective compared to conventional DMARDs, but may be cost-effective compared to other DMARDs. The variability in economic outcomes across different income-level countries highlights the need for tailored evaluations. More consistent and comprehensive economic evaluations are necessary to inform policy and market access strategies for rheumatoid arthritis treatments. Further economic evaluations are needed to adapt to the evolving contexts of rheumatoid arthritis therapy. For more details please click the link! https://lnkd.in/d2tcHu-F #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Lower Cost And Targeted Therapies Biggest Need In Rheumatoid Arthritis (RA) 👉 Rheumatoid arthritis (RA), an #autoimmune inflammatory disease affects about 1% of the U.S. population, with a female to male ratio of 2:1 👉 The pathophysiology of RA involves a complex interplay of immune components, cytokines, and growth factors 👉 Disease-modifying anti-rheumatic drugs (DMARDs) are pivotal in slowing or halting RA progression and bone damage 👉 The latest additions in DMARDs armamentarium, JAK inhibitors, hinder the immune system from producing inflammation-causing enzymes. They can be used alone or in conjunction with other RA medications for enhanced efficacy 👉 Despite the availability of various DMARDs and biologics, achieving disease remission remains a challenge for many RA patients 👉 Bruton’s tyrosine kinase (BTK) inhibitors represents an #emerging class of drugs that are currently being studied in the clinical setting for the treatment of rheumatoid arthritis. At present, there are several orally administered BTK inhibitors in development. If successful, these inhibitors could broaden #therapeutic options for rheumatoid arthritis #treatment, either independently or as adjunctive therapies 👉 EOS Intelligence research reveals that less expensive drugs and more targeted agents are identified as the greatest #unmet needs in RA. Targeted therapies not only offer a solution for non/inadequate responders but also have the potential to reduce the overall cost of RA care. By eliminating the use of costly medications that may prove to be ineffective, targeted therapies could significantly impact the management of RA #eosintelligence #perspectives #marketresearch #competitiveintelligence #rheumatoidarthritis #autoimmunedisease #strategy #pharmaceuticals #biotech #leadership #marketing #healthcare

"The medicines that mimic the Glp-1 hormone then became blockbusters. With close to half of the world’s population expected to be obese or overweight by 2030, according to the World Obesity Federation, demand for these drugs is surging—Bloomberg, a data provider, estimates that these medications will hit $80bn in yearly sales by then. The market is projected to grow by 26% per year in the next five years, compared with 16% per year for oncology drugs and 4% per year for immunology medicines, the two other biggest areas." https://lnkd.in/gxYXqyRr

For those with rheumatoid arthritis (RA), this study suggests that clinical treatment guidelines should be updated to include the initiation of biosimilars immediately after the failure of a certain drug. https://ow.ly/QUvl50SI6Cu #rheumatoidarthritis #arthritis #autoimmunedisease

The Economist projects GLP-1 medications to increase in market size ‘…by 26% per year in the next five years, compared with 16% per year for oncology drugs and 4% per year for immunology medicines.’ Liraglutide and semaglutide, developed by Novo Nordisk, and tirzepatide from Eli Lilly and Company are likely to be usurped by over 100 drugs in pipeline that ‘…are easier to take, cause fewer side-effects or result in more effective weight loss.’ Daniel Drucker, at Mount Sinai Hospital (Toronto), Sinai Health found that in mice suffering from extensive inflammation throughout the body, GLP-1 drugs reduced the condition; these drugs might be useful for treating Alzheimer’s disease and Parkinson’s disease, brain disorders that are characterized by inflammation. In addition, GLP-1 drugs may curb cravings, such as alcohol-use disorder, and other ‘…other addictive substances such as tobacco or marijuana.’ https://lnkd.in/evfGQXM4

On September 5, 2024, the FDA upgraded FILSPARI from conditional approval to full approval for treating IgA nephropathy, a kidney disease. This full approval extends its use, allowing the small molecule blocker to slow kidney function decline in adults at risk of disease progression without requiring a specific urinary protein level as before. FILSPARI, a first-in-class, orally active single molecule, is a high-affinity dual antagonist of the ETA and AT1 receptors, both of which are implicated in kidney disease development. It is notable as the first non-immunosuppressive drug approved in the IgAN treatment space, initially receiving accelerated approval in February 2023. With this new approval, FILSPARI will compete with Novartis' FABHALTA, which gained accelerated approval last month, and Calliditas Therapeutics' TARPEYO, approved in December 2023. Additionally, Novartis' atrasentan, a selective ETA receptor inhibitor, is under FDA review. Beyond these therapies, FILSPARI will face stiff competition from upcoming drugs. Key players developing IgAN therapies include Visterra Inc. (sibeprenlimab), Vera Therapeutics, Inc. (Atacicept), and RemeGen Biosciences (telitacicept). Get detailed insights on how the IgAN treatment landscape is changing with FILSPARI approval @ https://lnkd.in/gyMDGF92

Mechanism of action of anti-failure durgs according to pathophysiology of HFpEF: 1- The mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, are recommended for patients with symptomatic heart failure with ejection fraction of 35% or less. There is increased risk of of hyperkalemia and worsening renal function in patients with borderline or preserved ejection fraction. However, MRAs may be safe in a selected group of patients with heart failure and concomitant diabetes mellitus or renal insufficiency. 2- PDE-5 inhibitiotors drugs: this class does not result in significant improvement in exercise capacity or clinical status in patients with HFpEF. Furthermore, continued efforts to identify key pathophysiologic perturbations and novel therapeutic targets in HFpEF are needed. 3- ARNI (angiotensin receptor/neprilysin inhibitor) durgs: they are a newer treatment for heart failure. The combination of sacubitril and valsartan has helped people live longer and have a better quality of life. 4- Guanylyl cyclase activators (GC activators) drugs: used in the treatment of myocardial ischemia include the NO donors nitroprusside and the organic nitrates, nitroglycerin and isosorbide dinitrate. Evidence of efficacy is lacking in treatment of patients with HFpEF, and they are generally are considered ineffective. 5- ACEI/ARB and beta-blockers are recommended by ACCF/AHA Practical Guidelines on HF for patients with DM, even without HF symptoms. Cardioprotective effect of carvedilol has been confirmed in these patients. 6- Calcium channel blockers: they are generally used as third and fourth line therapy for hypertension in patients with HFpEF. 7- Diuretics are the primary treatment for reducing congestive symptoms associated with hypervolemia. However, the required doses in most patients with HFpEF are substantially lower than one might use in HFrEF because HFpEF patients are more preload dependent. Image credit: https://lnkd.in/dMK2em2w #MedEducation #HFpEF #PerioperativeCare

Conclusions: * Innovation in small molecule drugs that are at risk under the IRA. * The "IRA" may reduce economic incentives to develop multiple indications. * Single-indication launches and investments in post-approval research for additional indications is severely diminished. * CMS Releases List of 10 Drugs Subject to Price Negotiation Under the IRA (diseases states from diabetes to heart failure to rheumatoid arthritis and cancer are impacted) Apixaban (Eliquis) Empagliflozin (Jardiance) Rivaroxaban (Xarelto) Sitagliptin (Januvia) Dapagliflozin (Farxiga) Sacubitril/valsartan (Entresto) Etanercept (Enbrel) Ibrutinib (Imbruvica) https://lnkd.in/eAZujzWE https://lnkd.in/eqTvBRA4 #drugdevelopment #clinicalresearch #FDA #goverment #IRA

Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. The approved drugs to treat ALS include RILUZOLE, RADICAVA, TIGLUTIK, EXSERVAN, and QALSODY.  However, after the setback with RELYVRIO, RADICAVA emerged as the leading contender in the current ALS market and is anticipated to achieve the highest revenue. Although the ALS pipeline holds multiple promising therapies such as Masitinib (AB Science), Ibudilast (MediciNova, Inc.), Ulefnersen (Ionis Pharmaceuticals, Inc.), TPN-101 (transposon therapeutics) and other various stages of development, the failure rates of clinical trials are quite high for ALS. Therapies like arimoclomol (Orphazyme), levosimendan (Orion Pharmaceuticals), ravulizumab (Ultomiris), and Zilucoplan (UCB Pharma), are some recent failures in the list of therapies for ALS, and more may follow in the future. Despite the challenges and setbacks in the ALS treatment landscape, the approval of drugs like Radicava ORS and QALSODY, along with a promising pipeline of emerging therapies, offer hope for improving the lives of ALS patients. Get an in-depth analysis of the evolving ALS treatment landscape at: https://lnkd.in/geF9ZqnW #ALS #AmyotrophicLateralSclerosis #NoCure #ALSResearch #ALSDrugs #Riluzole #Radicava #Tiglutik #Exservan #Qalsody #Relyvrio #Masitinib #Ibudilast #Ulefnersen #TPN101 #ClinicalTrials #DrugDevelopment #ALSChallenges #ALSSetbacks #RadicavaORS #PromisingTherapies #HopeForALS #NeurodegenerativeDiseases #MedicalResearch #Pharmaceuticals #Biotech #HealthcareInnovation #ALSawareness